Censo Biotechnologies and Axol announce merger and $5.3m investment
Investors in this round: Par Equity, Calculus Capital, Scottish Enterprise, Dr Jonathan Milner
Par Portfolio Company, CENSO Biotechnologies has announced its successful merger with Axol Bioscience Ltd, provider of iPSC-derived cells, media, and characterization services.
This exciting merger is underpinned by £3.8m of growth funding coming from Par Equity, Calculus Capital, Scottish Enterprise and Dr. Jonathan Milner.
The combined group forms a platform with significant revenues and a breath of service to ensure it is well placed to scale further as a leading provider of product and service solutions in a fast growing, specialist market for iPSC-based neuroscience, immune cell, and cardiac modelling utilised in drug discovery and screening.
Congratulations to the team on delivering this transaction – we look forward to working with you to scale the business further.
Read more here: https://bit.ly/3vFf3mE